Skip to main content

Advertisement

Correction to: Role of Bruton’s tyrosine kinase in B cells and malignancies

Article metrics

  • 472 Accesses

  • 2 Citations

The original article was published in Molecular Cancer 2018 17:57

Correction to: Mol Cancer

https://doi.org/10.1186/s12943-018-0779-z

Following publication of the original article [1], the authors reported an error in Table 1. Incorrect value was placed under Efficacy (column), R/R non-GCB DLBCL (row).The value 92% was captured instead of 35%. Corrected table is shown below. The authors would like to apologize for this error.

Table 1 Clinical trials with BTK inhibitors in B cell malignancies

Reference

  1. 1.

    Singh PS, Dammeijer F, Hendriks RW. Role of Bruton’s tyrosine kinase in B cellsand malignancies. Mol Cancer. 2018;17:57 https://doi.org/10.1186/s12943-018-0779-z.

Download references

Author information

Correspondence to Rudi W. Hendriks.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article